Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Studies from Queen's University further understanding of bladder cancer
October 7th, 2008
"The intra-cavitary administration of antineoplastic agents for the treatment of non-invasive bladder cancer has met with variable results. Mytomicin-C (MCC) is effective in the prevention of tumor recurrence when administered in the immediate post-resection period, but also exhibits activity against papillary tumors," scientists in Kingston, Canada report. "It lacks efficacy in carcinoma in-situ (CIS) of the bladder. Bacillus Calmette-Guerin (BCG) has been shown to be effective against papillary tumors, but particularly in the treatment of CIS. Unfortunately, live BCG has serious safety limitations. To review the current situation with the use of non-viable...
Source: Cancer Weekly (2008-10-07)
|
